Found 89 articles
Exoskeleton Robotic System Market (Type, Application) Size Worth USD 4.22Bn, Globally, by 2028 Growing at 23.0% CAGR | Exclusive Report by The Insight Partners
According to our new research study on "Exoskeleton Robotic System Market Forecast to 2028 – COVID-19 Impact and Global Analysis
NurExone Reports First Quarter 2023 Financial Results and Provides Corporate Update
NurExone Biologic Inc. has released its financial results for the quarter ended March 31, 2023.
Exo Announces Lead Program, Targeting TANK Binding Kinase 1 (TBK1), for the Treatment of Autoimmune Diseases
Exo Therapeutics, Inc. today announced its lead program directed against TBK1, and the appointment of Alexandra Joseph, PhD, as Executive Vice President of Biology.
Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium
Apollomics Inc. announced that the company’s Co-Founder and President, Sanjeev Redkar, MBA, Ph.D., will speak at the 23rd Annual R. Bryan Miller Symposium, an event exploring the interface of chemical biology and organic chemistry in honor of Professor R. Bryan Miller, at the University of California, Davis on April 14, 2023.
KeifeRx Appoints Garrett Vygantas, MD, MBA, to Board of Directors
KeifeRx announced the appointment of Garrett Vygantas, MD, MBA, to serve on the Company's Board of Directors.
Exo Therapeutics Appoints Nagesh Mahanthappa as Executive Chair
Exo Therapeutics, Inc. today announced the appointment of Nagesh Mahanthappa, PhD, to Executive Chair.
New Orleans' Physician Uses Regenerative Medicine to Repair Neurocognitive Trauma and Diseases
Many Americans suffer from impaired cognition, autonomic nervous system function, and physiologic functioning related to memory loss, Alzheimer's sleep apnea, anxiety, depression, attention deficit disorders, and even traumatic brain injuries (TBI).
Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million
Novadip Biosciences announced that it has raised an additional EUR 40 million in a Series B equity round and non-dilutive funding.
Pegfilgrastim Biosimilar Market Trends and Growth Factors Analysis 2020 – 2030
Biosimilar is referred to a medical product that is similar to existing drug produced by a well-established company.
BrainStorm Cell Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Corporate Update
BrainStorm Cell Therapeutics today announced financial results for the second quarter ended June 30, 2022, and provided a corporate update.
Emergent Acquires Evolutionary Biologics, Former L’Oréal President Jim Morrison to Become Full Time CEO of Emergent Effective August 15, 2022
Emergent Health Corp. announces it has acquired Evolutionary Biologics, Inc.
Roundworms are the cornerstone of scientific discoveries that have helped shape how we understand human disease and treatment. BioSpace takes a look at advances in C. elegans research.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Transition Bio Closes $50 Million Series A Financing to Accelerate Biomolecular Condensate Drug Discovery
Round led by Northpond Ventures, with participation from Taiho Ventures, Bristol Myers Squibb, Lifeforce Capital and Magnetic Ventures.
Exo Therapeutics Appoints Stephanos Ioannidis as Executive Vice President, Drug Discovery and Catherine Scholz as Senior Vice President, Program Management
Exo Therapeutics, Inc. , a company pioneering the discovery and development of small molecules that can reprogram protein targets through binding to exosites, today announced the appointments of Stephanos Ioannidis, PhD, as Executive Vice President, Drug Discovery and Catherine Scholz, PharmD, as Senior Vice President, Program Management.
BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the financial results for the first quarter ended March 31, 2022 and provided a corporate update.
BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco Meeting
BrainStorm Cell Therapeutics Inc. announced the presentation of a poster titled, "MSC-NTF derived small extracellular vesicles display superior macrophage immunomodulation compared with vesicles derived from naïve MSCs," at the International Society of Cell & Gene Therapy ISCT 2022 Meeting, being held from May 4-7, 2022 in San Francisco, CA.
BrainStorm Announces Upcoming Scientific Conference Presentations - May 03, 2022
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announces presentations at upcoming scientific conferences in May 2022.
Exo Therapeutics Appoints Laura Kiessling to Scientific Advisory Board
Exo Therapeutics, Inc. today announced the appointment of Laura Kiessling, PhD, to the company’s Scientific Advisory Board (SAB).
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.